Sei Investments Co. grew its position in shares of Liquidia Corporation (NASDAQ:LQDA – Free Report) by 306.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 35,655 shares of the company’s stock after purchasing an additional 26,879 shares during the quarter. Sei Investments Co.’s holdings in Liquidia were worth $1,346,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Liquidia by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after buying an additional 1,700 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Liquidia by 10.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Liquidia by 15.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after purchasing an additional 16,022 shares in the last quarter. Creative Planning grew its stake in shares of Liquidia by 40.7% in the 2nd quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after purchasing an additional 7,765 shares during the last quarter. Finally, Legal & General Group Plc grew its stake in shares of Liquidia by 13.4% in the 2nd quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after purchasing an additional 11,111 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.
Liquidia Stock Down 3.3%
NASDAQ:LQDA opened at $88.05 on Wednesday. The business’s fifty day moving average price is $77.76 and its 200 day moving average price is $54.51. The firm has a market capitalization of $7.83 billion, a price-to-earnings ratio of 628.97 and a beta of 0.58. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 1-year low of $21.15 and a 1-year high of $93.61.
Insider Transactions at Liquidia
In other news, Director Stephen M. Bloch sold 242,269 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $70.43, for a total value of $17,063,005.67. Following the completion of the sale, the director directly owned 1,176,184 shares of the company’s stock, valued at $82,838,639.12. This represents a 17.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Paul B. Manning sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $63.91, for a total transaction of $12,782,000.00. Following the sale, the director owned 716,311 shares of the company’s stock, valued at approximately $45,779,436.01. This represents a 21.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 1,781,861 shares of company stock worth $124,407,112 in the last quarter. 25.60% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
A number of analysts recently weighed in on the stock. Oppenheimer set a $75.00 target price on shares of Liquidia in a report on Friday, June 5th. Piper Sandler set a $129.00 price objective on Liquidia in a research note on Friday, July 24th. Royal Bank Of Canada set a $130.00 target price on Liquidia in a research report on Friday, July 24th. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Liquidia currently has an average rating of “Moderate Buy” and an average target price of $86.18.
Get Our Latest Analysis on Liquidia
About Liquidia
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Featured Stories
- Five stocks we like better than Liquidia
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Want to see what other hedge funds are holding LQDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Liquidia Corporation (NASDAQ:LQDA – Free Report).
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
